Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

2.

Park

JH

,

Riviere

I

,

Gonen

M

, et al.

Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia

.

N Engl J Med

.

2018

;

378

(

5

):

449

-

459

.

3.

Liu

E

,

Marin

D

,

Banerjee

P

, et al.

Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors

.

N Engl J Med

.

2020

;

382

(

6

):

545

-

553

.

4.

Marin

D

,

Li

Y

,

Basar

R

, et al.

Safety, efficacy and determinants of response of allogeneic CD19^–specific CAR-NK cells in CD19⁺ B cell tumors: a phase 1/2 trial

.

Nat Med

.

2024

;

30

(

3

):

772

-

784

.

5.

Tang

X

,

Yang

L

,

Li

Z

, et al.

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia

.

Am J Cancer Res

.

2018

;

8

(

6

):

1083

-

1089

.

6.

Pan

K

,

Farrukh

H

,

Chittepu

V

,

Xu

H

,

Pan

CX

,

Zhu

Z

.

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

.

J Exp Clin Cancer Res

.

2022

;

41

(

1

):

119

.

7.

Rafiq

S

,

Hackett

CS

,

Brentjens

RJ

.

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

.

Nat Rev Clin Oncol

.

2020

;

17

(

3

):

147

-

167

.

8.

Korell

F

,

Berger

TR

,

Maus

MV

.

Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes

.

Med

.

2022

;

3

(

8

):

538

-

564

.

9.

Sterner

RC

,

Sterner

RM

.

CAR-T cell therapy: current limitations and potential strategies

.

Blood Cancer J

.

2021

;

11

(

4

):

69

.

10.

Messmer

AS

,

Que

YA

,

Schankin

C

, et al.

CAR T-cell therapy and critical care : a survival guide for medical emergency teams

.

Wien Klin Wochenschr

.

2021

;

133

(

23-24

):

1318

-

1325

.

11.

Gust

J

,

Hay

KA

,

Hanafi

LA

, et al.

Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells

.

Cancer Discov

.

2017

;

7

(

12

):

1404

-

1419

.

12.

Olson

ML

,

Mause

ERV

,

Radhakrishnan

SV

, et al.

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

.

Leukemia

.

2022

;

36

(

7

):

1943

-

1946

.

13.

Ghorashian

S

,

Kramer

AM

,

Onuoha

S

, et al.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

.

Nat Med

.

2019

;

25

(

9

):

1408

-

1414

.

14.

Zhou

X

,

Cao

H

,

Fang

SY

, et al.

CTLA-4 tail fusion enhances CAR-T antitumor immunity

.

Nat Immunol

.

2023

;

24

(

9

):

1499

-

1510

.

15.

Li

Y

,

Basar

R

,

Wang

G

, et al.

KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

.

Nat Med

.

2022

;

28

(

10

):

2133

-

2144

.

16.

Sakemura

RL

,

Manriquez Roman

C

,

Horvei

P

, et al.

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

.

Blood

.

2024

;

143

(

3

):

258

-

271

.

17.

Liu

E

,

Tong

Y

,

Dotti

G

, et al.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

.

Leukemia

.

2018

;

32

(

2

):

520

-

531

.

18.

Salles

G

,

Dlugosz-Danecka

M

,

Ghesquieres

H

,

Jurczak

W

.

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

.

Expert Opin Biol Ther

.

2021

;

21

(

4

):

455

-

463

.

19.

Ilieva

K

,

Eberl

M

,

Jaehrling

J

, et al.

Preclinical study of CD19 detection methods post tafasitamab treatment

.

Front Immunol

.

2023

;

14

:

1274556

.

20.

Rico

LG

,

Bardina

J

,

Bistue-Rovira

A

, et al.

Accurate identification of cell doublet profiles: comparison of light scattering with fluorescence measurement techniques

.

Cytometry A

.

2023

;

103

(

5

):

447

-

454

.

21.

McComb

S

,

Nguyen

T

,

Shepherd

A

, et al.

Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through hinge domain truncation

.

Front Immunol

.

2022

;

13

:

864868

.

22.

Smith

SH

,

Rigley

KP

,

Callard

RE

.

Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms

.

Immunology

.

1991

;

73

(

3

):

293

-

297

.

23.

Rezvani

K

,

Rouce

R

,

Liu

E

,

Shpall

E

.

Engineering natural killer cells for cancer immunotherapy

.

Mol Ther

.

2017

;

25

(

8

):

1769

-

1781

.

24.

Lim

WA

,

June

CH

.

The principles of engineering immune cells to treat cancer

.

Cell

.

2017

;

168

(

4

):

724

-

740

.

25.

Scott

AM

,

Wolchok

JD

,

Old

LJ

.

Antibody therapy of cancer

.

Nat Rev Cancer

.

2012

;

12

(

4

):

278

-

287

.

26.

Paul

S

,

Konig

MF

,

Pardoll

DM

, et al.

Cancer therapy with antibodies

.

Nat Rev Cancer

.

2024

;

24

(

6

):

399

-

426

.

27.

Zhang

Y

,

Patel

RP

,

Kim

KH

, et al.

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

.

Mol Cancer

.

2023

;

22

(

1

):

200

.

28.

Hamieh

M

,

Dobrin

A

,

Cabriolu

A

, et al.

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

.

Nature

.

2019

;

568

(

7750

):

112

-

116

.

29.

Aparicio-Perez

C

,

Carmona

M

,

Benabdellah

K

,

Herrera

C

.

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL

.

Front Immunol

.

2023

;

14

:

1165870

.

30.

Nakamura

K

,

Nakayama

M

,

Kawano

M

, et al.

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

.

Proc Natl Acad Sci U S A

.

2013

;

110

(

23

):

9421

-

9426

.

31.

Ramezani

F

,

Panahi Meymandi

AR

,

Akbari

B

, et al.

Outsmarting trogocytosis to boost CAR NK/T cell therapy

.

Mol Cancer

.

2023

;

22

(

1

):

183

.

32.

Spiegel

JY

,

Patel

S

,

Muffly

L

, et al.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

.

Nat Med

.

2021

;

27

(

8

):

1419

-

1431

.

33.

Temming

AR

,

Bentlage

AEH

,

de Taeye

SW

, et al.

Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding

.

Mol Immunol

.

2020

;

127

:

79

-

86

.

34.

Ramello

MC

,

Haura

EB

,

Abate-Daga

D

.

CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

.

Pharmacol Res

.

2018

;

129

:

194

-

203

.

35.

Nguyen

A

,

Johanning

G

,

Shi

Y

.

Emerging novel combined CAR-T cell therapies

.

Cancers (Basel)

.

2022

;

14

(

6

):

1403

.